Single Cell & Spatial Analysis in the Tumour Microenvironment
AGENDA OVERVIEW
2.00pm Thought Leader Interview with Professor Evan Keller
2.30pm Panel Discussion: Unlocking the Tumour Microenvironment: Advances in Single Cell & Spatial Analysis
- How spatial and single-cell technologies are reshaping our understanding of tumour heterogeneity
- Translating high-resolution tissue data into clinical decision-making and biomarker discovery
- Integrating multi-omic and imaging data: challenges in computation, standardisation, and scale
- Future directions in therapeutic targeting and personalised oncology through spatial biology
Panellists
Simpa S. Salami, Associate Professor of Urology and Associate Director, Rogel Cancer Center, University of Michigan
Carlo B. Bifulco, Chief Medical Officer, Providence Genomics; Director, Translational Molecular Pathology and Molecular Genomics, Earle A. Chiles Research Institute, Providence Cancer Institute
Egon Ranghini, PhD, Senior Science & Technology Advisor, 10x Genomics
Veera Baladandayuthapani, Chair and Professor of Biostatistics, University of Michigan School of Public Health; Professor of Computational Medicine & Bioinformatics; Associate Director of Quantitative Data Sciences and Director of the Cancer Data Science Shared Resource, Rogel Cancer Center
Biography:
Dr. Keller is the Richard and Susan Rogel Professor of Oncology and serves as Director of the Single Cell Spatial Analysis Program, Director of the Research Cores Office, and Associate Director of Shared Resources at the Rogel Cancer Center. He earned his Doctor of Veterinary Medicine from the University of California, Davis, and his Ph.D. in Developmental Biology from the University of Wisconsin–Madison. Dr. Keller is Board Certified in Oncology by the American College of Veterinary Internal Medicine. He has authored more than 250 publications, and his research centers on the tumor microenvironment, spanning fundamental biological investigations through to clinical applications.
Translating AI-Enabled Multi-Omics Diagnostics into Clinical Practice: Regulatory, Reimbursement, and Adoption Pathways
Presented by Junmei Cairns, Associate Director at AstraZeneca
Scaling AI-Driven Pathology into Clinical and Commercial Diagnostics
AGENDA OVERVIEW
10 March 2026 – 15.30 to 16.30 UK Time
15.30 Thought Leadership Interview: The Emerging Era of Computational Precision Biomarkers
Eric Walk, Chief Medical Officer, PathAI
15.45 Thought Leadership Interview: Pioneering the Future of Diagnostics: AI and Innovation in Pathology
Dr. Muhammed Aslam, Consultant Pathologist, Betsi Cadwaladr University Health Board; Clinical Lead for Wales Digital Pathology/AI
16.00 Panel Discussion: Computational Precision Biomarkers & Spatial Pathology - The Next Frontier in Precision Diagnostics
- Integrating AI in CDx, spatial pathology, and translational data - Integrating AI in CDx, spatial pathology and how translational data informs diagnosis, prognosis, and treatment strategies.
- Scaling innovation across public and private sectors: collaborations between the NHS, biotech, AI startups, and healthtech; the role of leadership in aligning efforts.
- Opportunities in Precision Biomarkers and Commercialisation
Moderated by Darren Davis, Director, Precision for Medicine
Panellists:
John LE QUESNE, Professor, University of Glasgow
Eric Walk, Chief Medical Officer, PathAI
Muhammed Aslam, Consultant Pathologist, Betsi Cadwaladr University Health Board; Clinical Lead for Wales Digital Pathology/AI
Biography:
Dr M B Aslam is a at Betsi Cadwaladr University Health Board with a special interest in digital pathology and artificial intelligence. He has played a key leadership role in the development and implementation of AI-enabled diagnostic services across Wales, including pioneering national deployment projects in prostate, breast, upper GI, and pan-cancer pathology.
With extensive experience in clinical leadership and NHS management, Dr Aslam currently serves as the national clinical lead for digital pathology and AI in Wales. His work focuses on enhancing diagnostic quality, reducing turnaround times, and supporting the digital transformation of pathology services.
